1. Home
  2. TNGX

as 09-12-2025 11:35am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Founded: 2014 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 723.2M IPO Year: N/A
Target Price: $10.00 AVG Volume (30 days): 1.3M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.32 EPS Growth: N/A
52 Week Low/High: $1.03 - $10.85 Next Earning Date: 11-05-2025
Revenue: $24,296,000 Revenue Growth: -42.84%
Revenue Growth (this year): 6.56% Revenue Growth (next year): -52.42%

TNGX Daily Stock ML Predictions

Stock Insider Trading Activity of Tango Therapeutics Inc. (TNGX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Third Rock Ventures IV, L.P. TNGX 10% Owner Sep 8 '25 Sell $7.04 86,459 $608,628.13 14,727,516
Third Rock Ventures IV, L.P. TNGX 10% Owner Sep 5 '25 Sell $7.00 642,906 $4,500,342.00 14,727,516
Third Rock Ventures IV, L.P. TNGX N/A Aug 22 '25 Sell $7.00 302,194 $2,115,358.00 14,727,516
Third Rock Ventures IV, L.P. TNGX N/A Aug 19 '25 Sell $7.01 1,100,000 $7,712,760.00 14,727,516

Share on Social Networks: